Mucolipidosis II and III alpha/beta in Brazil: analysis of the GNPTAB gene

G K Cury1, U Matte, O Artigalás

  • 1Post Graduate Program in Medicine, Medical Sciences, Universidade Federal do Rio Grande do Sul, Brazil. gcury1@hotmail.com

Gene
|April 10, 2013
PubMed
Abstract

Insights

This study identified nine GNPTAB gene variations in Brazilian patients with Mucolipidosis II and III alpha/beta, with exon 19 mutations being most frequent. These findings aid in diagnosing rare lysosomal storage diseases.

Area of Science:

  • Genetics
  • Biochemistry
  • Rare Diseases

Background:

  • Mucolipidosis II and III (MLII and MLIII) alpha/beta are rare autosomal recessive lysosomal storage diseases.
  • These conditions stem from pathogenic variations in the GNPTAB gene, which encodes subunits of the phosphotransferase enzyme.
  • This enzyme is crucial for synthesizing the mannose-6-phosphate marker, essential for lysosomal enzyme targeting.

Purpose of the Study:

  • To identify sequence variations in the GNPTAB gene among Brazilian patients diagnosed with MLII and MLIII alpha/beta.
  • To contribute to a better understanding of the genetic basis of these rare lysosomal storage diseases in the Brazilian population.

Main Methods:

  • Genomic DNA (gDNA) was extracted from the peripheral blood of patients diagnosed with MLII/III.
  • The GNPTAB gene was sequenced to identify genetic variations.
  • cDNA analysis was used to confirm the deleterious effect of specific mutations on splicing.

Main Results:

  • Twelve unrelated Brazilian patients with MLII/III were analyzed.
  • Nine distinct causal sequence variations in the GNPTAB gene were identified.
  • The mutation c.3503_3504delTC in exon 19 was the most prevalent pathogenic variation, found in 11 out of 24 alleles.

Conclusions:

  • The GNPTAB gene exhibits significant allelic heterogeneity in Brazilian patients with MLII and MLIII.
  • Genetic screening for MLII and MLIII in Brazil should prioritize mutations in exon 19 of the GNPTAB gene.
  • Further investigations are planned for patients with unidentified pathogenic mutations.

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...